Inovio Pharmaceuticals (INO) Scheduled to Post Earnings on Thursday

Inovio Pharmaceuticals (NASDAQ:INO) will release its earnings data after the market closes on Thursday, November 14th. Analysts expect Inovio Pharmaceuticals to post earnings of ($1.20) per share for the quarter.

Inovio Pharmaceuticals (NASDAQ:INO) last released its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($1.19) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.10) by ($0.09). The firm had revenue of $0.10 million during the quarter, compared to analyst estimates of $0.10 million. During the same period in the previous year, the company posted ($1.56) EPS. On average, analysts expect Inovio Pharmaceuticals to post $-5 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Inovio Pharmaceuticals Stock Down 0.4 %

NASDAQ INO opened at $5.65 on Thursday. The firm’s 50-day moving average is $5.99 and its two-hundred day moving average is $8.44. Inovio Pharmaceuticals has a 12 month low of $3.89 and a 12 month high of $14.75.

Wall Street Analyst Weigh In

Several research firms recently weighed in on INO. HC Wainwright reiterated a “neutral” rating and issued a $15.00 target price on shares of Inovio Pharmaceuticals in a report on Monday, July 15th. Oppenheimer decreased their target price on Inovio Pharmaceuticals from $40.00 to $33.00 and set an “outperform” rating on the stock in a research note on Monday, August 12th. Finally, Royal Bank of Canada dropped their target price on Inovio Pharmaceuticals from $8.00 to $7.00 and set a “sector perform” rating for the company in a research report on Friday, October 4th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the stock. According to MarketBeat, Inovio Pharmaceuticals presently has a consensus rating of “Hold” and a consensus target price of $43.80.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.